{"id":"W4226263934","doi":"10.2337/dc21-2034","title":"Safety of Empagliflozin in Patients With Type 2 Diabetes and Chronic Kidney Disease: Pooled Analysis of Placebo-Controlled Clinical Trials","year":2022,"lang":"en","type":"article","venue":"Diabetes Care","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":44,"is_retracted":false,"has_abstract":true,"ca_institutions":"University of British Columbia","funders":"National Center for Advancing Translational Sciences; National Heart, Lung, and Blood Institute; Sanofi Genzyme; Centers for Disease Control and Prevention; National Institutes of Health; Eli Lilly and Company; Ono Pharmaceutical; Chugai Pharmaceutical; Akebia Therapeutics; Mitsubishi Tanabe Pharma Corporation; Relypsa; Astellas Pharma; Novo Nordisk; Nipro; Kidney Foundation of Canada; National Institute of Diabetes and Digestive and Kidney Diseases; Sanofi; Kowa Company; U.S. Department of Veterans Affairs; Alexion Pharmaceuticals; Daiichi Sankyo Europe; Gilead Sciences; Heart and Stroke Foundation of Canada; Kissei; AstraZeneca; GlaxoSmithKline; Amgen","keywords":"Empagliflozin; Medicine; Placebo; Internal medicine; Kidney disease; Discontinuation; Diabetes mellitus; Type 2 diabetes; Hazard ratio; Proportional hazards model; Clinical trial; Adverse effect; Randomized controlled trial; Surgery; Confidence interval; Endocrinology; Pathology","routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001245709,0.000222041,0.002118835,0.0005687152,0.00005008581,0.000008929456,0.0001152522,0.00004857766,0.0003921959],"category_scores_gemma":[0.000915125,0.0001660059,0.0004113784,0.0009762988,0.0001009065,0.00005307819,0.0001550746,0.0001422403,0.000001939653],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0001607201,"about_ca_system_score_gemma":0.0002110233,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.000003535207,"about_ca_topic_score_gemma":0.000009575473,"domain_scores_codex":[0.9971809,0.0006190218,0.00104734,0.0003808498,0.0004615245,0.00031041],"domain_scores_gemma":[0.9980475,0.0006238783,0.0004844232,0.0004289156,0.000172112,0.0002432046],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.006024295,0.0006530185,0.9763152,0.0003218773,0.009065438,0.000002452757,0.0001757227,0.0002301919,0.00004557366,0.00001943753,0.0002791056,0.0068677],"study_design_scores_gemma":[0.0458512,0.002330366,0.9300528,0.0001389935,0.01956634,2.6494e-9,0.0002501127,0.001068895,0.00009007532,0.00000690751,0.0004863423,0.0001579354],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9944487,0.002600809,4.358153e-7,0.0001171035,0.0001202288,0.001897214,0.0005840953,0.00002118656,0.0002101782],"genre_scores_gemma":[0.9974464,0.00006757454,0.00004529226,0.0002154729,0.00002849916,0.0001912363,0.001900922,0.00002386373,0.00008078471],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.04626236,"threshold_uncertainty_score":0.6769524,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01395502804113343,"score_gpt":0.2923727435065641,"score_spread":0.2784177154654306,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}